Research Funded To Date

Since inception $91 million invested in a cure for brain cancer

PHASE II, OPEN-LABEL STUDY TO ESTIMATE THE OVERALL RESPONSE RATES OF OLAPARIB IN SUBJECTS WITH RECURRENT/PROGRESSIVE IDH1/2-MUTANT SOLID TUMORS IN 3 COHORTS (GLIOMA, CHOLANGIOCARCINOMA, AND OTHER SOLID MALIGNANT TUMORS).

PI: Patricia LoRusso, DO
Professor of Medicine; Associate Director of Experimental Therapeutics
Yale Cancer Center

Award: $50,000

DEVELOPMENT OF A PROJECT TO CREATE AND DEPLOY AN ULTRA-RAPID CLINICAL TEST TO COMPREHENSIVELY PROFILE THE GENOMES OF PATIENTS WITH RECURRENT GLIOBLASTOMA.

PI: Timothy K. McDaniel, Ph.D.
Sr. Vice President of Emerging Opportunities
Translational Genomics Research Institute (TGen)

Award: $34,406

DEVELOPMENT OF A PROJECT TO ASSESS SINGLE CELL RNA SEQUENCING AS A QUALITY CONTROL METRIC IN THE INDUSTRIAL MANUFACTURE OF CHIMERIC ANTIGEN RECEPTOR T (CAR T) CELLS.

PI: Nicholas Banovich, Ph.D.
Assistant Professor in the Integrated Cancer Genomics Division
Translational Genomics Research Institute (TGen)

Award: $65,594

NEUROLOGICAL SCIENCES INTERNSHIP PROGRAM AT TGEN DESIGNED TO GIVE HIGH SCHOOL AND UNDERGRADUATE STUDENTS INTENSIVE, HANDS-ON RESEARCH EXPERIENCE WORKING ALONGSIDE A MENTOR-SCIENTIST TO LEARN ABOUT TRANSLATIONAL RESEARCH WHILE INVESTIGATING QUESTIONS WITHIN THE NEUROLOGICAL SCIENCES.

PI: Julie Euber
Manager of Education and Outreach
Translational Genomics Research Institute (TGen)

 

Award: $87,484

ESTABLISH A PHOENIX-BASED CENTER FOR GLIOBLASTOMA DRUG DISCOVERY – THE IVY BRAIN TUMOR RESEARCH CENTER-EMPHASIZING INDUSTRY-PARTNERED DRUG DEVELOPMENT PAIRED WITH A LARGE PORTFOLIO OF PHASE 0/II TRIALS AND RANDOMIZED PHASE II TRIALS.

PI: Nader Sanai, M.D., FAANS, FACS
Director, Division of Neurosurgical Oncology
Director, Barrow Brain Tumor Research Center
Barrow Neurological Institute

 

Award: $25,000,000 over ten years
BACK TO TOP
Close Menu